We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Location: United Kingdom, England, Alderley Edge
Employees: 11-50
Total raised: $5.82M
Founded date: 2016
Investors 1
| Date | Name | Website |
| 20.11.2022 | Perscitus ... | perscitusl... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2026 | - | $5.82M | - |
Mentions in press and media 2
| Date | Title | Description |
| 12.05.2026 | Infex Therapeutics Raises £4.3M in Funding | Infex Therapeutics, a Macclesfield, Cheshire, UK-based developer of novel anti-infective therapies for drug-resistant infections, raised £4.3m in funding. The round was led by Jon Moulton, with participation from the GM&C Life Sciences ... |
| - | Infex Therapeutics | “Infex Therapeutics – Vital new drugs for pandemic infections” |